Elsevier and Iktos have partnered to strengthen Elsevier’s chemistry solution, Reaxys, by combining the company’s chemistry data with synthetic planning AI technologies developed by Iktos. The partnership aims to support R&D organisations to decrease the time required to complete Design-Make-Test-Analyse cycles of small molecules, thus reducing… Read More
As part of a new collaboration, Iktos’ generative design technology and Curreio’s cryo-electron microscopy (cryo-EM) platform will be combined to design novel preclinical drug candidates for an undisclosed target. Iktos’ Makya generative AI technology aims to bring new insights and directions into the molecular discovery process… Read More
Iktos has raised €15.5m in a Series A funding round to expand its artificial intelligence-based drug discovery technologies and solutions. The round was co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. The financing will enable the company… Read More
